Another recent paper by D’Francisco et al. [46] highlighted, using Doppler US, a reduction in blood flow anomalies and an increase in the arterial resistivity index in patients with BPH 30 days after an experimental treatment with acyline, a third-generation GnRH antagonist. This evidence concerns the gene GNRH1 and benign prostatic hyperplasia.